CD274 and posterior cortical atrophy: Additionally, our study delves into the realm of immune checkpoint inhibitors (ICIs), particularly targeting the PD-1/PD-L1 axis, a novel therapeutic avenue in PCa management, especially in metastatic CRPC [37].